Jump to main content
Jump to site search

Issue 36, 2017
Previous Article Next Article

Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(IV) prodrug for liver cancer therapy

Author affiliations

Abstract

Chemotherapy is the most common therapeutic strategy for the treatment of unresectable hepatocellular carcinoma. However, the therapeutic efficacy is limited by the low delivery efficiency of chemotherapeutics and severe toxicity towards healthy tissues. To address these challenges, active-targeting mesoporous silica nanoparticles conjugating a platinum(IV) prodrug were developed as a therapy for liver cancer for the first time. Taking advantage of liver-targeting lactobionic acid (LA), the smart nano-carriers not only enhanced the circulation time, but also effectively concentrated at the liver tumor site. Moreover, the conjugated platinum(IV) could be reduced in the reductive tumor environment for the fast release of active platinum(II). The novel targeting and self-responsive drug-loading system offers new prospects for liver cancer chemotherapy.

Graphical abstract: Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(iv) prodrug for liver cancer therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 21 Jun 2017, accepted on 21 Aug 2017 and first published on 21 Aug 2017


Article type: Paper
DOI: 10.1039/C7TB01704A
Citation: J. Mater. Chem. B, 2017,5, 7591-7597
  •   Request permissions

    Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(IV) prodrug for liver cancer therapy

    Z. Wang, P. Wu, Z. He, H. He, W. Rong, J. Li, D. Zhou and Y. Huang, J. Mater. Chem. B, 2017, 5, 7591
    DOI: 10.1039/C7TB01704A

Search articles by author

Spotlight

Advertisements